287 related articles for article (PubMed ID: 32568377)
1. PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation?
Yehia L; Eng C
Hum Mol Genet; 2020 Oct; 29(R2):R150-R157. PubMed ID: 32568377
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
3. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
5. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
Mester JL; Moore RA; Eng C
Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
[TBL] [Abstract][Full Text] [Related]
6. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
Orloff MS; Eng C
Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
[TBL] [Abstract][Full Text] [Related]
7. Novel dermatological and skeletal features associated with PTEN variant in PTEN hamartoma tumor syndrome.
Comeau D; Allain V; Maillet-Lebel N; Ben Amor M
Eur J Med Genet; 2023 Aug; 66(8):104798. PubMed ID: 37307869
[TBL] [Abstract][Full Text] [Related]
8. Cowden syndrome.
Gustafson S; Zbuk KM; Scacheri C; Eng C
Semin Oncol; 2007 Oct; 34(5):428-34. PubMed ID: 17920899
[TBL] [Abstract][Full Text] [Related]
9. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
10. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F;
J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809
[TBL] [Abstract][Full Text] [Related]
11. 65 YEARS OF THE DOUBLE HELIX: One gene, many endocrine and metabolic syndromes:
Yehia L; Eng C
Endocr Relat Cancer; 2018 Aug; 25(8):T121-T140. PubMed ID: 29792313
[TBL] [Abstract][Full Text] [Related]
12. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
Ngeow J; Eng C
Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications for Germline PTEN Spectrum Disorders.
Ngeow J; Sesock K; Eng C
Endocrinol Metab Clin North Am; 2017 Jun; 46(2):503-517. PubMed ID: 28476234
[TBL] [Abstract][Full Text] [Related]
14. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model.
Mester JL; Tilot AK; Rybicki LA; Frazier TW; Eng C
Eur J Hum Genet; 2011 Jul; 19(7):763-8. PubMed ID: 21343951
[TBL] [Abstract][Full Text] [Related]
15. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.
Orloff MS; He X; Peterson C; Chen F; Chen JL; Mester JL; Eng C
Am J Hum Genet; 2013 Jan; 92(1):76-80. PubMed ID: 23246288
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Spectrum of
Yehia L; Keel E; Eng C
Annu Rev Med; 2020 Jan; 71():103-116. PubMed ID: 31433956
[No Abstract] [Full Text] [Related]
17. Germline mutations in the PTEN gene in Israeli patients with Bannayan-Riley-Ruvalcaba syndrome and women with familial breast cancer.
Figer A; Kaplan A; Frydman M; Lev D; Paswell J; Papa MZ; Goldman B; Friedman E
Clin Genet; 2002 Oct; 62(4):298-302. PubMed ID: 12372056
[TBL] [Abstract][Full Text] [Related]
18. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
[TBL] [Abstract][Full Text] [Related]
19. Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.
Jaini R; Loya MG; King AT; Thacker S; Sarn NB; Yu Q; Stark GR; Eng C
Hum Mol Genet; 2020 Aug; 29(14):2353-2364. PubMed ID: 32588888
[TBL] [Abstract][Full Text] [Related]
20. Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer.
Shiovitz S; Everett J; Huang SC; Orloff MS; Eng C; Gruber SB
Breast Cancer Res Treat; 2010 Nov; 124(2):459-65. PubMed ID: 20349131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]